Theralase Technologies Inc.

TLTFF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue$1,033$1,070$1,139$781
% Growth-3.4%-6%45.9%
Cost of Goods Sold$479$508$510$471
Gross Profit$554$562$628$310
% Margin53.6%52.5%55.2%39.7%
R&D Expenses$2,754$2,982$4,281$2,925
G&A Expenses$1,944$2,030$1,442$1,753
SG&A Expenses$2,049$2,127$1,530$1,850
Sales & Mktg Exp.$105$97$88$97
Other Operating Expenses$40$47$49$77
Operating Expenses$4,842$5,309$5,860$4,851
Operating Income-$4,288-$4,594-$5,232-$4,542
% Margin-415%-429.2%-459.5%-581.8%
Other Income/Exp. Net$32$23-$4$130
Pre-Tax Income-$4,256-$4,571-$5,235-$4,411
Tax Expense$0$0$0$0
Net Income-$4,256-$4,571-$5,235-$4,411
% Margin-411.8%-427.1%-459.8%-565.1%
EPS-0.018-0.021-0.025-0.022
% Growth14.9%17.5%-16.7%
EPS Diluted-0.018-0.021-0.025-0.022
Weighted Avg Shares Out240,069219,968207,924204,276
Weighted Avg Shares Out Dil240,069219,968207,924204,276
Supplemental Information
Interest Income$66$50$31$23
Interest Expense$24$30$21$5
Depreciation & Amortization$272$286$313$276
EBITDA-$3,960-$4,254-$4,901-$4,130
% Margin-383.2%-397.5%-430.4%-529%